Skip to main content

Table 1 Study and patient characteristics for the 65 delirium trials

From: Heterogeneity in design and analysis of ICU delirium randomized trials: a systematic review

 

Overall

Prevention

Treatment

Both

n = 65

n = 44

n = 12

n = 9

Study characteristics

 Sample size, median [Q1,Q3]

113 [70, 198]

109 [70, 158]

104 [72, 238]

141[101, 164]

 Study start year, median [Q1, Q3]

2012 [2009, 2014]

2013 [2009, 2014]

2009 [2005, 2012]

2010 [2009, 2011]

 Fundinga

  Governmental funding

20 (31)

9 (21)

5 (42)

6 (67)

  No external funding

18 (28)

12 (27)

3 (25)

3 (33)

  Industry funding

8 (12)

5 (11)

2 (17)

1 (11)

  Non-profit sources (non-gov’t)

5 (8)

3 (7)

2 (17)

0 (0)

  Other source of funding

7 (11)

6 (14)

0 (0)

1 (11)

  Unclear funding source

16 (25)

13 (30)

3 (25)

0 (0)

 Country/regiona

  USA

16 (25)

10 (23)

4 (33)

2 (22)

  China

12 (19)

10 (23)

1 (8)

1 (11)

  Iran

8 (12)

7 (16)

1 (8)

0 (0)

  Canada

5 (8)

4 (9)

1 (8)

0 (0)

  Europeb

5 (8)

2 (5)

0 (0)

3 (33)

  Japan

2 (3)

2 (5)

0 (0)

0 (0)

  Otherc

21 (32)

12 (27)

5 (42)

3 (33)

 Patient typea,e

  Cardiac surgery

22 (34)

16 (36)

3 (25)

3 (33)

  Surgery

19 (29)

15 (34)

3 (325)

1 (11)

  ARFf

17 (26)

10 (23)

3 (25)

4 (44)

  Medical

6 (9)

2 (5)

3 (25)

1 (11)

  Other

14 (22)

6 (14)

6 (50)

2 (22)

 ICU typea

  General or mixedd

13 (20)

6 (14)

4 (33)

3 (33)

  Surgical

11 (17)

6 (14)

4 (33)

1 (11)

  Cardiovascular surgery

10 (15)

10 (23)

0 (0)

0 (0)

  Medical

9 (14)

4 (9)

4 (33)

1 (11)

  Coronary care

1 (2)

0 (0)

0 (0)

1 (11)

  Unspecified

28 (43)

20 (46)

5 (42)

3 (33)

Patient characteristics

 Average age, median [Q1,Q3]

62 [59, 69]

63 [59, 69]

62 [55, 65]

66 [63, 68]

 Proportion male, median [Q1,Q3]

62 [53, 72]

63 [55, 70]

61 [51374]

58 [50, 60]

 Severity of illness measurea

  APACHE II

23 (35)

13 (29.5)

7 (58)

3 (33)

  APACHE III

2 (3)

1 (2)

0 (0)

1 (11)

  APACHE IV

1 (2)

1 (2)

0 (0)

0 (0)

  SAPS II

1 (2)

1 (2)

0 (0)

0 (0)

  SAPS III

1 (2)

1 (2)

0 (0)

0 (0)

  SOFA

6 (9)

4 (9)

1 (8)

1 (11)

 Average APACHE II, median [Q1,Q3]

15 [11, 20]

15 [11, 18]

13 [11, 20]

20 [18, 21]

 Average SOFA, median [Q1,Q3]

5 [4, 7]

4 [4, 5]

6 [6, 6]

9 [9, 9]

  1. Values in the table are count (%) unless otherwise noted. The RCTs may be counted in several categories for each characteristic, so that the count (%) will not necessarily sum to 65 (100%)
  2. Abbreviation: ARF Acute respiratory failure
  3. aMultiple categories could be selected for each delirium RCT, so that the count (%) will not necessarily sum to 65 (100%)
  4. bEurope includes Switzerland (1 prevention trial), Italy (1 prevention trial, 1 prevention/treatment trial), and Great Britain (2 prevention/treatment trials)
  5. cOther includes Egypt (3), Netherlands (3), Turkey (3), South Korea (2), Thailand (2), Australia (1), Belgium (1), Chile (1), India (1), Saudia Arabia (1), and Serbia (1)
  6. dMixed ICU is a medical-surgical ICU
  7. eCardiac surgery and general surgery are mutually exclusive. If a trial recruited both cardiac and non-cardiac surgery patients, it was classified as general surgery. Surgery includes patients with a “trauma” designation
  8. fAcute respiratory failure includes trials conducted among mechanically ventilated, acute respiratory, or acute respiratory distress syndrome patients